D-0666-2017 Class II Terminated

Recalled by Medisca, Inc. — Plattsburgh, NY

FDA drug recall D-0666-2017 was initiated by Medisca, Inc. on Apr 3, 2017 and is designated Class II. Reason for recall: cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection The recall status is terminated (terminated Jun 18, 2019).

Recall details

Product Type
Drugs
Report Date
Apr 19, 2017
Initiation Date
Apr 3, 2017
Termination Date
Jun 18, 2019
Voluntary/Mandated
Voluntary: Firm initiated

Product description

ESTRADIOL, USP Bulk (Hemihydrate), in a) 25 g (NDC 38779-2261-04) and b) 100 g (NDC 38779-2261-05) bottles, Packed by MEDISCA INC. PLATTSBURGH, NY Product Code 2261

Reason for recall

cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection

Distribution pattern

Nationwide, Australia, Bahamas, Italy, Singapore, Thailand, United Kingdom

Code information

a) 129669/C, 129669/F, 129669/H, 129669/J, 130941/B 130941/D, 130941/F, 136108/B, 139091/B; b) 129669/B, 129669/E, 130941/A, 130941/C, 130941/E,130941/G, 136108/A,

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0666-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0666-2017. Report a data issue: hello@regdatalab.com.